Back to Search Start Over

Combined Heart-Lung-Liver Transplantation for Patients With Cystic Fibrosis: The Australian Experience

Authors :
Katherine A. Stuart
A. Carew
P. Hodgkinson
Peter Hopkins
A. Fiene
Peter T. Bell
C. Divithotawela
Daniel C. Chambers
Source :
Transplantation Proceedings. 53:2382-2389
Publication Year :
2021
Publisher :
Elsevier BV, 2021.

Abstract

Background Combined multivisceral transplantation has emerged as a therapeutic option for a select patient cohort; however, clinical decision-making remains complex and controversial. The aim of this study was to examine patient characteristics, operative complications, and long-term outcomes of all patients who have undergone combined heart-lung-liver transplantation (HLLTx) in Australia. Methods In this study, we performed a retrospective analysis of all adult patients who have undergone combined HLLTx in Australia to date. Recipient clinical characteristics, waitlist, and transplant outcomes are described. Results Eight adult patients have received HLLTx at a single Australian transplant center. Recipients of HLLTx have typically been young (median age, 30.1 years; range, 24-37), underweight (median body mass index, 19.8 kg/m2; range, 16.2-30.4) patients with cystic fibrosis (n = 8, 100%) with severe airflow obstruction (median forced expiratory volume in the first second of expiration, 24% predicted; range, 17%-48%) accompanied by liver cirrhosis confirmed on histopathology (n = 8, 100%). Despite relative preservation of synthetic function and low model for end-stage liver disease scores (median, 8; range, 6-17), all recipients had complications of portal hypertension prior to transplantation, with many patients having suffered life-threatening variceal hemorrhage. In this cohort, HLLTx was associated with overall posttransplant survival of 87.5% at 30 days, 71.4% at 1 year, and 42.9% at 5 years. Listing for combined HLLTx was associated with prolonged waitlist times relative to bilateral sequential single-lung transplantation (median 556 vs 56 days, respectively), however waitlist mortality and/or delisting was comparable between groups. Conclusions Taken together, these findings highlight the opportunities and challenges facing combined (heart-) lung and liver transplantation in patients with multiorgan failure.

Details

ISSN :
00411345
Volume :
53
Database :
OpenAIRE
Journal :
Transplantation Proceedings
Accession number :
edsair.doi.dedup.....af1071b584c36f3cb7cdaaf7887920b2